Immune Checkpoint Inhibitors in Oncology Market Report: 2027-2031 Forecast, Strategic Opportunities by Indication, Target, Product, Molecule Format, Treatment Setting and Country - Strategic Analysis of 25 Companies

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2.1 Forecast Approach
2.2 Data Sources
2.3 Scope & Definitions
2.4 Limitations

3.1 Mechanism of Action & Key Components
3.2 Evolution of the Technology
3.3 Adjacent Modalities

4.1 Global Market Overview by Country
4.2 Global Market by Indication - Overview
4.3 Global Market by Target - Overview
4.4 Global Market by Product - Overview
4.5 Global Market by Molecule Format - Overview
4.6 Global Market by Treatment Setting - Overview

5.1 Approved Product Registry
5.2 Technology Benchmarking
5.3 Commercial Benchmarking - Top-Selling Products
5.4 Regulatory Risk Case Studies

6.1 Pipeline Overview
6.2 Pipeline Distribution by Phase
6.3 Target & Indication Crowding
6.4 Sponsor Geographic Distribution

7.1 Core Platform Technologies
7.2 Next-Generation Approaches
7.3 Delivery & Formulation
7.4 Platform Technology Licensors

8.1 Combinations with Immunotherapy
8.2 Combinations with Targeted Therapy
8.3 Commercial and Biological Rationale

9.1 FDA Approval Pathways
9.2 EMA & NMPA Pathways
9.3 HTA & Reimbursement Dynamics
9.4 Patent & Biosimilar Overview

10.1 Expiry Timeline
10.2 Biosimilar & Generic Pipeline
10.3 Anticipated Price Erosion

11.1 Key Originators
11.2 Why Global Pharma Is Buying In

12.1 Recent Developments - Importance and How to Use This Section
12.2 Imfinzi approved as first perioperative immunotherapy for early gastric cancer
12.3 Keytruda plus Padcev approved before and after surgery in bladder cancer
12.4 AbbVie licenses RemeGen's PD-1/VEGF bispecific for up to $5.6 billion
12.5 Keytruda and Opdivo left off Medicare's 2028 negotiation list
12.6 Ivonescimab misses interim goal in global HARMONi-3 trial
12.7 Trodelvy plus Keytruda approved for first-line PD-L1-positive triple-negative breast cancer
12.8 Samsung Bioepis reports first global Phase 3 data for a Keytruda biosimilar
12.9 Summit updates ivonescimab survival data ahead of FDA decision
12.10 Keytruda plus Padcev approval extended to all surgery-eligible bladder cancer patients
12.11 FDA accepts the first Keytruda biosimilar application for review

13.1 Manufacturing Capacity Landscape
13.2 CDMO Competitive Positioning
13.3 In-House vs. Outsourced Manufacturing Trends
13.4 Capacity Bottlenecks and Outlook

14.1 Market Structure
14.2 Big Pharma / Large-Cap Portfolios
14.3 Emerging and China-Originated Players
14.4 Outlook

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Key Investment Risks

16.1 White-Space Opportunities
16.2 Partnering Strategy Guidance

17.1 Non-small cell lung cancer
17.2 Melanoma
17.3 Renal cell carcinoma
17.4 Head & neck cancer
17.5 Gastric & esophageal cancer
17.6 Urothelial cancer
17.7 Hepatocellular carcinoma
17.8 Breast & gynecologic cancers
17.9 Other indications

18.1 PD-1 inhibitors
18.2 PD-L1 inhibitors
18.3 CTLA-4 inhibitors
18.4 LAG-3 inhibitors
18.5 Next-generation targets (TIGIT, TIM-3, other)

19.1 Keytruda (pembrolizumab)
19.2 Opdivo (nivolumab)
19.3 Tecentriq (atezolizumab)
19.4 Imfinzi (durvalumab)
19.5 Libtayo (cemiplimab)
19.6 Yervoy (ipilimumab)
19.7 Opdualag (nivolumab + relatlimab)
19.8 China-originated PD-1 inhibitors
19.9 Biosimilars (pembrolizumab and nivolumab)

20.1 Monoclonal antibodies
20.2 Fixed-dose combinations
20.3 Bispecific antibodies (e.g., PD-1/VEGF)
20.4 Other formats

21.1 Perioperative & neoadjuvant
21.2 Adjuvant
21.3 First-line metastatic
21.4 Later-line

22.1 3SBio
22.2 Akeso
22.3 AstraZeneca
22.4 BeOne Medicines
22.5 BioNTech
22.6 Bristol Myers Squibb
22.7 Celltrion
22.8 Coherus BioSciences
22.9 Formycon
22.10 GSK
22.11 Halozyme Therapeutics
22.12 Hengrui Medicine
22.13 Incyte
22.14 Innovent Biologics
22.15 Junshi Biosciences
22.16 Merck & Co. (MSD)
22.17 Merck KGaA / Pfizer
22.18 Ono Pharmaceutical
22.19 Pfizer
22.20 Regeneron
22.21 RemeGen
22.22 Roche
22.23 Samsung Bioepis
22.24 Sandoz
22.25 Summit Therapeutics

23.1 Abbreviations
23.2 Report Limitations Restated

Table 1 Global Market by Country
Table 2 Global Market by Indication
Table 3 Global Market by Target
Table 4 Global Market by Product
Table 5 Global Market by Molecule Format
Table 6 Global Market by Treatment Setting
Table 7 Non-small cell lung cancer by Country
Table 8 Melanoma by Country
Table 9 Renal cell carcinoma by Country
Table 10 Head & neck cancer by Country
Table 11 Gastric & esophageal cancer by Country
Table 12 Urothelial cancer by Country
Table 13 Hepatocellular carcinoma by Country
Table 14 Breast & gynecologic cancers by Country
Table 15 Other indications by Country
Table 16 PD-1 inhibitors by Country
Table 17 PD-L1 inhibitors by Country
Table 18 CTLA-4 inhibitors by Country
Table 19 LAG-3 inhibitors by Country
Table 20 Next-generation targets (TIGIT, TIM-3, other) by Country
Table 21 Keytruda (pembrolizumab) by Country
Table 22 Opdivo (nivolumab) by Country
Table 23 Tecentriq (atezolizumab) by Country
Table 24 Imfinzi (durvalumab) by Country
Table 25 Libtayo (cemiplimab) by Country
Table 26 Yervoy (ipilimumab) by Country
Table 27 Opdualag (nivolumab + relatlimab) by Country
Table 28 China-originated PD-1 inhibitors by Country
Table 29 Biosimilars (pembrolizumab and nivolumab) by Country
Table 30 Monoclonal antibodies by Country
Table 31 Fixed-dose combinations by Country
Table 32 Bispecific antibodies (e.g., PD-1/VEGF) by Country
Table 33 Other formats by Country
Table 34 Perioperative & neoadjuvant by Country
Table 35 Adjuvant by Country
Table 36 First-line metastatic by Country
Table 37 Later-line by Country

Figure 1 Key Graphic - The checkpoint patent cliff
Figure 1 Global Market Pareto Chart
Figure 2 Global Market by Indication - Base vs. Final
Figure 3 Global Market by Indication Base Year
Figure 4 Global Market by Indication End Year
Figure 5 Indication Share by Year
Figure 6 Indication Segments Growth
Figure 7 Global Market by Target - Base vs. Final
Figure 8 Global Market by Target Base Year
Figure 9 Global Market by Target End Year
Figure 10 Target Share by Year
Figure 11 Target Segments Growth
Figure 12 Global Market by Product - Base vs. Final
Figure 13 Global Market by Product Base Year
Figure 14 Global Market by Product End Year
Figure 15 Product Share by Year
Figure 16 Product Segments Growth
Figure 17 Global Market by Molecule Format - Base vs. Final
Figure 18 Global Market by Molecule Format Base Year
Figure 19 Global Market by Molecule Format End Year
Figure 20 Molecule Format Share by Year
Figure 21 Molecule Format Segments Growth
Figure 22 Global Market by Treatment Setting - Base vs. Final
Figure 23 Global Market by Treatment Setting Base Year
Figure 24 Global Market by Treatment Setting End Year
Figure 25 Treatment Setting Share by Year
Figure 26 Treatment Setting Segments Growth
Figure 27 Non-small cell lung cancer Growth
Figure 28 Melanoma Growth
Figure 29 Renal cell carcinoma Growth
Figure 30 Head & neck cancer Growth
Figure 31 Gastric & esophageal cancer Growth
Figure 32 Urothelial cancer Growth
Figure 33 Hepatocellular carcinoma Growth
Figure 34 Breast & gynecologic cancers Growth
Figure 35 Other indications Growth
Figure 36 PD-1 inhibitors Growth
Figure 37 PD-L1 inhibitors Growth
Figure 38 CTLA-4 inhibitors Growth
Figure 39 LAG-3 inhibitors Growth
Figure 40 Next-generation targets (TIGIT, TIM-3, other) Growth
Figure 41 Keytruda (pembrolizumab) Growth
Figure 42 Opdivo (nivolumab) Growth
Figure 43 Tecentriq (atezolizumab) Growth
Figure 44 Imfinzi (durvalumab) Growth
Figure 45 Libtayo (cemiplimab) Growth
Figure 46 Yervoy (ipilimumab) Growth
Figure 47 Opdualag (nivolumab + relatlimab) Growth
Figure 48 China-originated PD-1 inhibitors Growth
Figure 49 Biosimilars (pembrolizumab and nivolumab) Growth
Figure 50 Monoclonal antibodies Growth
Figure 51 Fixed-dose combinations Growth
Figure 52 Bispecific antibodies (e.g., PD-1/VEGF) Growth
Figure 53 Other formats Growth
Figure 54 Perioperative & neoadjuvant Growth
Figure 55 Adjuvant Growth
Figure 56 First-line metastatic Growth
Figure 57 Later-line Growth